Ex vivo engineered immune organoids for controlled germinal center reactions.

Ex vivo engineered three-dimensional organotypic cultures have enabled the real-time study and control of biological functioning of mammalian tissues. Organs of broad interest where its architectural, cellular, and molecular complexity has prevented progress in ex vivo engineering are the secondary immune organs. Ex vivo immune organs can enable mechanistic understanding of the immune system and more importantly, accelerate the translation of immunotherapies as well as a deeper understanding of the mechanisms that lead to their malignant transformation into a variety of B and T cell malignancies. However, till date, no modular ex vivo immune organ has been developed with an ability to control the rate of immune reaction through tunable design parameter. Here we describe a B cell follicle organoid made of nanocomposite biomaterials, which recapitulates the anatomical microenvironment of a lymphoid tissue that provides the basis to induce an accelerated germinal center (GC) reaction by continuously providing extracellular matrix (ECM) and cell-cell signals to naïve B cells. Compared to existing co-cultures, immune organoids provide a control over primary B cell proliferation with ∼100-fold higher and rapid differentiation to the GC phenotype with robust antibody class switching.

[1]  J. Chaudhuri,et al.  Specific recruitment of protein kinase A to the immunoglobulin locus regulates class-switch recombination , 2009, Nature Immunology.

[2]  D. Levy,et al.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.

[3]  C. Berek,et al.  Maturation of the immune response in germinal centers , 1991, Cell.

[4]  I. Maclennan,et al.  Mechanism of antigen-driven selection in germinal centres , 1989, Nature.

[5]  G. Inghirami,et al.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. , 2003, Blood.

[6]  J. Licht,et al.  Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells , 2004, Nature Medicine.

[7]  Alexander D. MacKerell,et al.  A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. , 2013, Cell reports.

[8]  ZilberbergJenny,et al.  Patient-specific 3D microfluidic tissue model for multiple myeloma. , 2014 .

[9]  T. Reiman,et al.  A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. , 2008, Blood.

[10]  T. Honjo,et al.  Separate domains of AID are required for somatic hypermutation and class-switch recombination , 2004, Nature Immunology.

[11]  O. Elemento,et al.  Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity , 2013, PLoS genetics.

[12]  J. Cyster,et al.  Integrin-Mediated Interactions between B Cells and Follicular Dendritic Cells Influence Germinal Center B Cell Fitness , 2014, The Journal of Immunology.

[13]  Takeshi Watanabe,et al.  Generation of a synthetic lymphoid tissue–like organoid in mice , 2004, Nature Biotechnology.

[14]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[15]  Burkhard Ludewig,et al.  Form follows function: lymphoid tissue microarchitecture in antimicrobial immune defence , 2008, Nature Reviews Immunology.

[16]  A. Sonnenberg,et al.  Extracellular matrix of secondary lymphoid organs impacts on B-cell fate and survival , 2013, Proceedings of the National Academy of Sciences.

[17]  Nicholas A Peppas,et al.  Hydrogels and Scaffolds for Immunomodulation , 2014, Advanced materials.

[18]  A. Melnick,et al.  Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications , 2014, Cellular and molecular bioengineering.

[19]  J. Cyster,et al.  Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5 , 2004, Nature Immunology.

[20]  S. Grupp,et al.  RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. , 2004, Blood.

[21]  R. Gascoyne,et al.  MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. , 2012, Cancer cell.

[22]  Ashutosh Kumar Singh,et al.  Engineering vaccines and niches for immune modulation. , 2014, Acta biomaterialia.

[23]  Feng Zhao,et al.  Increasing Mechanical Strength of Gelatin Hydrogels by Divalent Metal Ion Removal , 2014, Scientific Reports.

[24]  Jinsong Wei,et al.  Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. , 2009, Blood.

[25]  S. Serrano,et al.  Innate lymphoid cells integrate stromal and immune signals to enhance antibody production by splenic marginal zone B cells , 2014, Nature Immunology.

[26]  K. Anderson,et al.  Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. , 2002, Blood.

[27]  A. Khademhosseini,et al.  Transdermal regulation of vascular network bioengineering using a photopolymerizable methacrylated gelatin hydrogel. , 2013, Biomaterials.

[28]  Horst Kessler,et al.  Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation , 2010, Anti-cancer agents in medicinal chemistry.

[29]  Thomas C. Ferrante,et al.  A combinatorial cell-laden gel microarray for inducing osteogenic differentiation of human mesenchymal stem cells , 2014, Scientific Reports.

[30]  M. Carroll,et al.  Follicular dendritic cells: dynamic antigen libraries , 2014, Nature Reviews Immunology.

[31]  A. Melnick,et al.  A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. , 2009, Blood.

[32]  J. Gribben,et al.  CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. , 1997, The Journal of clinical investigation.

[33]  Jie Liu,et al.  Spheroid body-forming cells in the human gastric cancer cell line MKN-45 possess cancer stem cell properties , 2012, International journal of oncology.

[34]  D. Kitamura,et al.  In-vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo. , 2011, Nature communications.

[35]  M. Scott,et al.  An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway , 2001, Science.

[36]  Alexander D. MacKerell,et al.  A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. , 2010, Cancer cell.

[37]  Akhilesh K Gaharwar,et al.  Nanomaterials for Engineering Stem Cell Responses , 2015, Advanced healthcare materials.

[38]  Bin Duan,et al.  Stiffness and adhesivity control aortic valve interstitial cell behavior within hyaluronic acid based hydrogels. , 2013, Acta biomaterialia.

[39]  Ashutosh Kumar Singh,et al.  In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. , 2009, Biomaterials.

[40]  Phillips Jm,et al.  Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity , 2022 .

[41]  Nathaniel S Wang,et al.  Molecular programming of B cell memory , 2011, Nature Reviews Immunology.

[42]  J. C. Love,et al.  In vivo discovery of immunotherapy targets in the tumour microenvironment , 2014, Nature.

[43]  T. Clozel,et al.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. , 2013, Cancer discovery.

[44]  T. Fujita,et al.  Scanning electron microscope studies of human Spleen , 1983, Survey of immunologic research.

[45]  N. Harindranath,et al.  CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line. , 1998, Journal of immunology.

[46]  S. Akira,et al.  CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells , 2003, Nature Immunology.

[47]  N. Harindranath,et al.  CD 40 Ligand and Appropriate Cytokines Induce Switching to IgG , IgA , and IgE and Coordinated Germinal Center and Plasmacytoid Phenotypic Differentiation in a Human Monoclonal IgM 1 IgD 1 B Cell Line 1 , 1998 .

[48]  F. Ross,et al.  Superactivation of integrin alphavbeta3 by low antagonist concentrations. , 2001, Journal of cell science.

[49]  A. Khademhosseini,et al.  Shear-Thinning Nanocomposite Hydrogels for the Treatment of Hemorrhage , 2014, ACS nano.

[50]  Ashutosh Kumar Singh,et al.  An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[51]  Michael L. Dustin,et al.  In vivo imaging of germinal centres reveals a dynamic open structure , 2007, Nature.

[52]  N. Munshi,et al.  A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells , 2011, Leukemia.

[53]  Riccardo Dalla-Favera,et al.  Germinal centres: role in B-cell physiology and malignancy , 2008, Nature Reviews Immunology.

[54]  Ali Khademhosseini,et al.  Nanocomposite hydrogels for biomedical applications. , 2014, Biotechnology and bioengineering.

[55]  T. Kinashi,et al.  Intracellular signalling controlling integrin activation in lymphocytes , 2005, Nature Reviews Immunology.

[56]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[57]  K. Aldape,et al.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[58]  F. Sciortino,et al.  Observation of empty liquids and equilibrium gels in a colloidal clay. , 2010, Nature materials.

[59]  Irene Puga,et al.  Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes , 2013, Nature Reviews Immunology.

[60]  R. Gascoyne,et al.  Sequential transcription factor targeting for diffuse large B-cell lymphomas. , 2008, Cancer research.

[61]  J. Walling,et al.  A purine scaffold Hsp90 inhibitor destabilizes Bcl6 and has specific anti-tumor activity in Bcl6 dependent B-cell lymphomas , 2009, Nature Medicine.

[62]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[63]  R. Gascoyne,et al.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. , 2010, The Journal of clinical investigation.

[64]  Manish K Jaiswal,et al.  Bioactive nanoengineered hydrogels for bone tissue engineering: a growth-factor-free approach. , 2015, ACS nano.

[65]  K. Tarte,et al.  Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells , 2012, Leukemia.

[66]  G. Botchkina,et al.  Hydrogel microstructure live-cell array for multiplexed analyses of cancer stem cells, tumor heterogeneity and differential drug response at single-element resolution. , 2016, Lab on a chip.

[67]  Ashutosh Kumar Singh,et al.  Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. , 2015, Blood.

[68]  Michael V Sefton,et al.  Endotoxin: the uninvited guest. , 2005, Biomaterials.

[69]  A. Sakamoto,et al.  Splenic CD19-CD35+B220+ cells function as an inducer of follicular dendritic cell network formation. , 2007, Blood.

[70]  Sebastian Hirsch,et al.  MR Elastography of the Liver and the Spleen Using a Piezoelectric Driver, Single‐Shot Wave‐Field Acquisition, and Multifrequency Dual Parameter Reconstruction , 2014, Magnetic resonance in medicine.

[71]  Jihun Kim,et al.  Wnt5a Is Secreted by Follicular Dendritic Cells To Protect Germinal Center B Cells via Wnt/Ca2+/NFAT/NF-κB–B Cell Lymphoma 6 Signaling , 2012, The Journal of Immunology.

[72]  Kristi S Anseth,et al.  Photocrosslinking of gelatin macromers to synthesize porous hydrogels that promote valvular interstitial cell function. , 2009, Tissue engineering. Part A.

[73]  D. Irvine,et al.  Lymphoid tissue engineering: invoking lymphoid tissue neogenesis in immunotherapy and models of immunity. , 2008, Seminars in immunology.

[74]  Klaus Rajewsky,et al.  Impairment of T-cell-dependent B-cell responses and B-l cell development in CD19-deficient mice , 1995, Nature.

[75]  M. Ferrarini,et al.  Ex-Vivo Dynamic 3-D Culture of Human Tissues in the RCCS™ Bioreactor Allows the Study of Multiple Myeloma Biology and Response to Therapy , 2013, PloS one.

[76]  Ashutosh Kumar Singh,et al.  Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[77]  A. Melnick,et al.  A peptomimetic inhibitor of BCL 6 with potent antilymphoma effects in vitro and in vivo , 2009 .

[78]  J. Banchereau,et al.  Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2 , 1996, The Journal of experimental medicine.